|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM333040562 |
| 003 |
DE-627 |
| 005 |
20240828231905.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/VIW.20200178
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1515.xml
|
| 035 |
|
|
|a (DE-627)NLM333040562
|
| 035 |
|
|
|a (NLM)34766160
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ma, Zetong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Therapeutic antibodies under development for SARS-CoV-2
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 28.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a © 2021 The Authors. VIEW published by Shanghai Fuji Technology Consulting Co., Ltd, authorized by Professional Community of Experimental Medicine, National Association of Health Industry and Enterprise Management (PCEM) and John Wiley & Sons Australia, Ltd.
|
| 520 |
|
|
|a The world is experiencing one of the most difficult moments in history with COVID-19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden. Efforts to fight the virus, including prevention and treatment, have never stopped. However, no specific drugs or treatments have yet been found. Antibody drugs have never been absent in epidemics such as SARS, MERS, HIV, Ebola, and so on in the past two decades. At present, while research on the SARS-CoV-2 vaccine is in full swing, antibody drugs are also receiving widespread attention. Several antibody drugs have successfully entered clinical trials and achieved impressive therapeutic effects. Here, we summarize the therapeutic antibodies against SARS-CoV-2, as well as the research using ACE2 recombinant protein or ACE2-Ig fusion protein
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Ig‐like proteins
|
| 650 |
|
4 |
|a SARS‐CoV
|
| 650 |
|
4 |
|a SARS‐CoV‐2
|
| 650 |
|
4 |
|a neutralization
|
| 700 |
1 |
|
|a Zhu, MengMei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Shuyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qian, Kewen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Chuqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fu, Wenyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lei, Changhai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Shi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t View (Beijing, China)
|d 2020
|g 3(2022), 2 vom: 27. März, Seite 20200178
|w (DE-627)NLM333040546
|x 2688-268X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:3
|g year:2022
|g number:2
|g day:27
|g month:03
|g pages:20200178
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/VIW.20200178
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_100
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_138
|
| 912 |
|
|
|a GBV_ILN_147
|
| 912 |
|
|
|a GBV_ILN_176
|
| 912 |
|
|
|a GBV_ILN_179
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_813
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2002
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2004
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2011
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2014
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a GBV_ILN_2016
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2020
|
| 912 |
|
|
|a GBV_ILN_2031
|
| 912 |
|
|
|a GBV_ILN_2039
|
| 912 |
|
|
|a GBV_ILN_2285
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 2022
|e 2
|b 27
|c 03
|h 20200178
|